Recent progress in tumour vaccine development.
Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.
Le Poole
I Caroline
IC
Oncology Institute, Loyola University Medical Center, 2160 S. 1st Ave, Maywood, IL 60153, USA. ilepool@lumc.edu
Bommiasamy
Hemamalini
H
Kast
W Martin
WM
D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000235:genetics; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics
D019496:Cancer Vaccines